MONDAY, SEPTEMBER 26, 2016

NIH launches HIV-related cardiovascular disease trial

The National Institute of Health announced Wednesday that researchers have begun enrolling participants in a multi-center international clinical trial to test whether statin administration can lower the risk of main adverse cardiovascular events in people with HIV.

The trial, supported by NIH’s National Heart, Lung and Blood Institute (NHLBI) and National Institute of Allergy and Infectious Diseases (NIAID), is known as the Randomized Trial to Prevent Vascular Events in HIV. The randomized trial is the largest to date that focuses on HIV-related cardiovascular disease.

“I am delighted that NHLBI and NIAID have joined forces to foster cross-disciplinary collaboration between cardiovascular and HIV researchers so that we can improve the lives of millions of people worldwide living with HIV and reduce the burden of cardiovascular disease,” NHLBI Director Gary Gibbons said.

Statins are a class of drugs that are safe and effective in lowering cholesterol levels and the risk of major adverse cardiovascular events in non-HIV populations.

“Research suggests that cholesterol-lowering statins may inhibit immune cell activation and inflammation and shrink arterial plaque,” NIAID Director Anthony Fauci said. “Therefore, these medications provide an intriguing possibility for improving cardiovascular outcomes in people with HIV.”

Organizations in this story

National Heart, Lung, and Blood Institute 31 Center Drive MSC 2486 Bethesda, MD 20892 ,

Get notified the next time we write about National Heart, Lung, and Blood Institute!